A phase 1, single-ascending dose trial studying lepodisiran, an extended-duration short interfering RNA targeting Lp(a), enrolled 48 adults elevated Lp(a) and no cardiovascular disease [98]. This evidence concerns the gene LPA and cardiovascular disorder.